266 related articles for article (PubMed ID: 16049125)
21. Developmental expression of the major human hepatic CYP3A enzymes.
Stevens JC; Hines RN; Gu C; Koukouritaki SB; Manro JR; Tandler PJ; Zaya MJ
J Pharmacol Exp Ther; 2003 Nov; 307(2):573-82. PubMed ID: 12975492
[TBL] [Abstract][Full Text] [Related]
22. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
Lown KS; Bailey DG; Fontana RJ; Janardan SK; Adair CH; Fortlage LA; Brown MB; Guo W; Watkins PB
J Clin Invest; 1997 May; 99(10):2545-53. PubMed ID: 9153299
[TBL] [Abstract][Full Text] [Related]
23. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.
Nakamura T; Sakaeda T; Horinouchi M; Tamura T; Aoyama N; Shirakawa T; Matsuo M; Kasuga M; Okumura K
Clin Pharmacol Ther; 2002 Apr; 71(4):297-303. PubMed ID: 11956513
[TBL] [Abstract][Full Text] [Related]
24. Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin.
Guo M; Dai X; Hu D; Zhang Y; Sun Y; Ren W; Wang L
Poult Sci; 2016 Sep; 95(9):2129-35. PubMed ID: 27118859
[TBL] [Abstract][Full Text] [Related]
25. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine.
Berggren S; Gall C; Wollnitz N; Ekelund M; Karlbom U; Hoogstraate J; Schrenk D; Lennernäs H
Mol Pharm; 2007; 4(2):252-7. PubMed ID: 17263554
[TBL] [Abstract][Full Text] [Related]
26. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta.
Schuetz JD; Kauma S; Guzelian PS
J Clin Invest; 1993 Aug; 92(2):1018-24. PubMed ID: 8349787
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
28. Grapefruit juice activates P-glycoprotein-mediated drug transport.
Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
[TBL] [Abstract][Full Text] [Related]
29. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.
Stevens JC
Drug Discov Today; 2006 May; 11(9-10):440-5. PubMed ID: 16635807
[TBL] [Abstract][Full Text] [Related]
30. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.
Thörn M; Finnström N; Lundgren S; Rane A; Lööf L
Br J Clin Pharmacol; 2005 Jul; 60(1):54-60. PubMed ID: 15963094
[TBL] [Abstract][Full Text] [Related]
31. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
32. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.
Suzuki H; Sugiyama Y
Eur J Pharm Sci; 2000 Nov; 12(1):3-12. PubMed ID: 11121729
[TBL] [Abstract][Full Text] [Related]
33. Differential regulation of CYP3A4 and CYP3A7 by dimethylsulfoxide in primary human hepatocytes.
Wilkening S; Bader A
Basic Clin Pharmacol Toxicol; 2004 Aug; 95(2):92-3. PubMed ID: 15379787
[No Abstract] [Full Text] [Related]
34. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient.
Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321
[TBL] [Abstract][Full Text] [Related]
35. Expression and localization of CYP3A4 and CYP3A5 in human lung.
Anttila S; Hukkanen J; Hakkola J; Stjernvall T; Beaune P; Edwards RJ; Boobis AR; Pelkonen O; Raunio H
Am J Respir Cell Mol Biol; 1997 Mar; 16(3):242-9. PubMed ID: 9070608
[TBL] [Abstract][Full Text] [Related]
36. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
37. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
38. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil.
Johnson BM; Charman WN; Porter CJ
J Pharm Pharmacol; 2001 Dec; 53(12):1611-9. PubMed ID: 11804391
[TBL] [Abstract][Full Text] [Related]
39. Effect of piperine and quercetin alone or in combination with marbofloxacin on CYP3A37 and MDR1 mRNA expression levels in broiler chickens.
Patel HB; Patel UD; Mathapati BS; Modi CM
Res Vet Sci; 2019 Oct; 126():178-183. PubMed ID: 31539794
[TBL] [Abstract][Full Text] [Related]
40. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.
Pinto AG; Horlander J; Chalasani N; Hamman M; Asghar A; Kolwankar D; Hall SD
Br J Clin Pharmacol; 2005 Apr; 59(4):440-6. PubMed ID: 15801939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
